StockData

Genelux vs Lyell Immunopharma

GNLX and LYEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GNLX and LYEL compare

Lyell Immunopharma is the larger company, worth 4.1 times as much as Genelux ($359M against $86.9M).

Lyell Immunopharma scores higher on the StockData Score (6 against 5 for Genelux), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGNLXLYEL
Size and price
Market cap$86.9M$359M
Share price$1.92$14.65
Change, 1 year−65.2%−15.9%
Change, 5 years–−92.1%
Beta (5Y)0.791.27
StockData Score
Total score56 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/S–13296×
P/B5.4×1.5× (better)
FCF yield−33.0% (better)−37.3%
Growth
Revenue growth (TTM)–−55.0%
Revenue growth, 5Y average–−65.9%
Profitability
Operating margin–−949981%
Net margin–−920285%
FCF margin–−496189%
Return on equity−178%−93.3% (better)
Return on invested capital–−782%
Financial health
Debt / equity0.000.00
Current ratio2.395.36 (better)
Altman Z-score−15.04−6.86 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield−21.7%–
Shareholder yield−21.7%0.00% (better)
Ownership
Held by institutions21.7%48.9%
Held by insiders7.7%45.0%
Insider net buying, 12 months−$341K$74.4M (better)
Short interest, % of float10.9%10.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.